{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:18:50Z","timestamp":1773465530154,"version":"3.50.1"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,10,26]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While simnotrelvir-ritonavir and nirmatrelvir-ritonavir, the oral antiviral agents targeting the 3C-like proteases, are widely used in China, robust data on their appropriate use remain limited in hospitalised patients. We therefore examined the appropriateness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in the inpatient setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted to compare the potentially inappropriate use of simnotrelvir-ritonavir and nirmatrelvir-ritonavir in hospitalised patients between 1 July 2023 and 31 December 2023 in Beijing, China. Four factors are taken into consideration when defining and critiquing potentially inappropriate use: indications, dosage and timing of administration, contraindications and drug\u2013drug interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We have identified 278 simnotrelvir-ritonavir and nirmatrelvir-ritonavir prescriptions in 226 hospitalised COVID-19 patients, of which 49.6% (138 prescriptions) satisfied all the criteria for appropriate use. Nirmatrelvir-ritonavir prescriptions were more likely to have potentially inappropriate indications (12.4% vs 3.2%, p=0.006) or dosage and timing of administration (13.1% vs 4.0%, p=0.009) than simnotrelvir-ritonavir prescriptions. Nirmatrelvir-ritonavir was prescribed to two patients in the presence of contraindications (severe renal impairment). No significant differences were identified in drug\u2013drug interactions (DDIs) (p=0.657) and contraindicated DDIs (p=0.670) between simnotrelvir-ritonavir and nirmatrelvir-ritonavir. The most common contraindicated co-medication was estazolam, followed by quetiapine and clopidogrel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>About half of the patients use simnotrelvir-ritonavir and nirmatrelvir-ritonavir that might potentially be inappropriate. More extensive research is required to supplement the empirical evidence supporting COVID-19 therapeutics. Additionally, appropriate therapy requires collaboration with pharmacists and education on the appropriate use of COVID-19 therapeutics among physicians and patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-003043","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:10:17Z","timestamp":1764875417000},"page":"e003043","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-402X","authenticated-orcid":false,"given":"Yuezhen","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-7529","authenticated-orcid":false,"given":"Chunguo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"},{"name":"Department of Pharmacy, Capital Medical University Beijing Obstetrics and Gynecology Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoling","family":"An","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2026010701522438000_12.1.e003043.1","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science"},{"key":"2026010701522438000_12.1.e003043.2","unstructured":"World Health Organization . COVID-19 epidemiological update - 13 august 2024. Available: https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update-edition-170 [Accessed 13 Sep 2024]."},{"key":"2026010701522438000_12.1.e003043.3","doi-asserted-by":"crossref","first-page":"107096","DOI":"10.1016\/j.ijantimicag.2024.107096","article-title":"Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis","volume":"63","author":"Zheng","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026010701522438000_12.1.e003043.4","first-page":"1812","article-title":"Expert consensus on the clinical application of oral small-molecule antiviral drugs against COVID-19","volume":"104","year":"2024","journal-title":"Chin Med J"},{"key":"2026010701522438000_12.1.e003043.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106598"},{"key":"2026010701522438000_12.1.e003043.6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsptsci.3c00134","article-title":"Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19","volume":"6","author":"Zhu","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026010701522438000_12.1.e003043.7","unstructured":"National Medical Products Administration . NMPA issued an emergency use authorization (EUA) for simnotrelvir plus ritonavir authorized for the treatment of mild and moderate covid-19 patients. Available: https:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/ypyw\/20230129143814163.html [Accessed 15 Apr 2024]."},{"key":"2026010701522438000_12.1.e003043.8","unstructured":"National Medical Products Administration . The state food and drug administration approved pfizer\u2019s new coronavirus treatment drug neimatevir tablet\/ritonavir tablet combination package for import registration under emergency conditions. Available: https:\/\/www.nmpa.gov.cn\/zhuanti\/yqyjzxd\/yqyjxd\/20220212085753142.html [Accessed 15 Apr 2024]."},{"key":"2026010701522438000_12.1.e003043.9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118542"},{"key":"2026010701522438000_12.1.e003043.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301425"},{"key":"2026010701522438000_12.1.e003043.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42102-y"},{"key":"2026010701522438000_12.1.e003043.12","doi-asserted-by":"crossref","first-page":"106857","DOI":"10.1016\/j.ijantimicag.2023.106857","article-title":"Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in China","volume":"62","author":"Shi","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026010701522438000_12.1.e003043.13","unstructured":"National Health Commission of the People\u2019s Republic of China, National administration of traditional Chinese medicine . Diagnosis and treatment protocol for covid-19. Available: http:\/\/www.nhc.gov.cn\/ylyjs\/pqt\/202301\/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml [Accessed 15 Apr 2024]."},{"key":"2026010701522438000_12.1.e003043.14","unstructured":"Paxlovid P . US food and drug administration fact sheet for healthcare providers: emergency use authorization for paxlovid. Available: https:\/\/ www.fda.gov\/media\/155050\/download [Accessed 6 Jan 2024]."},{"key":"2026010701522438000_12.1.e003043.15","unstructured":"Simcere . Simnotrelvir tablets\/ritonavir tablets(co-packaged). Available: https:\/\/3cl.simcere.com\/doctor\/index.html [Accessed 15 Apr 2025]."},{"key":"2026010701522438000_12.1.e003043.16","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and Comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026010701522438000_12.1.e003043.17","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.164"},{"key":"2026010701522438000_12.1.e003043.18","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect","volume":"75","author":"Stader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026010701522438000_12.1.e003043.19","unstructured":"University of Liverpool . COVID-19 drug interactions. Available: https:\/\/www.covid19-druginteractions.org\/checker [Accessed 21 Jan 2024]."},{"key":"2026010701522438000_12.1.e003043.20","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026010701522438000_12.1.e003043.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-001944","article-title":"Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19","volume":"11","author":"Zhang","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026010701522438000_12.1.e003043.22","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14072305","article-title":"Management of SARS-CoV-2 Infection-Clinical Practice Guidelines of the Polish Association of Epidemiologists and Infectiologists, for 2025","volume":"14","author":"Flisiak","year":"2025","journal-title":"J Clin Med"},{"key":"2026010701522438000_12.1.e003043.23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa2309002","article-title":"Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19","volume":"391","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010701522438000_12.1.e003043.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309003"},{"key":"2026010701522438000_12.1.e003043.25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature New Biol"},{"key":"2026010701522438000_12.1.e003043.26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cca.2021.12.004","article-title":"Performance verification of five commercial RT-qPCR diagnostic kits for SARS-CoV-2","volume":"525","author":"Yang","year":"2022","journal-title":"Clinica Chimica Acta"},{"key":"2026010701522438000_12.1.e003043.27","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac389","article-title":"Prevalence of Medical Contraindications to Nirmatrelvir\/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19","volume":"9","author":"Lim","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026010701522438000_12.1.e003043.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42140","article-title":"Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease","volume":"5","author":"Hoertel","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026010701522438000_12.1.e003043.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2022.101591"},{"key":"2026010701522438000_12.1.e003043.30","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.5005\/jp-journals-10071-23919","article-title":"Management of Drug\u2013Drug Interactions among Critically Ill Patients with Chronic Kidney Disease: Impact of Clinical Pharmacist\u2019s Interventions","volume":"25","author":"Aghili","year":"2021","journal-title":"Indian J Crit Care Med"},{"key":"2026010701522438000_12.1.e003043.31","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afv190"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-003043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:54:24Z","timestamp":1767779664000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-003043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjresp-2024-003043"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-003043","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}